Risperidone ER is under clinical development by Lyndra Therapeutics and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Risperidone ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Risperidone ER overview
Risperidone ER is under development for the treatment of schizophrenia, schizoaffective disorder and bipolar 1 disorder. It is administered through oral route. The drug candidate is formulated as extended-release capsule. It acts by targeting D2 receptor and 5-HT2 receptor. The drug candidate is developed based on ultra long-acting oral drug delivery technology. In this technology, the dosage form is encapsulated in a gelatin capsule and it has star-shaped configuration.
Lyndra Therapeutics overview
Lyndra Therapeutics, formerly Lyndra, is a biotechnology company. It is pioneering long-acting oral therapies, a potential major advance in oral drug delivery. The company develops oral dosage pills to reduce drug side effects and improve efficacy. Lyndra’s proprietary LYNX™ drug delivery platform is designed to deliver medicine for a week or longer in an oral form. Its drug delivery platform has the potential for broad applicability across multiple therapeutic areas – including approved drugs and those currently in development. Its partners include Bill & Melinda Gates Foundation, and the National Institutes of Health’s National Institute on Drug Abuse (NIDA). Lyndra Therapeutics is headquartered in Watertown, the US.
For a complete picture of Risperidone ER’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
